Novartis Q4 Results

↓ ↑ Content Click below to navigate through the document Cosentyx® - IL-17A inhibitor Company overview Financial review Conclusions Cosentyx® - IL-17A inhibitor Indication NCT05722522 (CAIN457012301) Rotator cuff tendinopathy Phase Phase 3 NCT05758415 (CAIN457012302) Indication Phase Rotator cuff tendinopathy Phase 3 Patients 234 Patients 234 Outcome Measures Change from BSL in in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) score [ Time Frame: At Week 16]: - Improving physical shoulder symptoms in participants with moderate to severe RCT at Week 16 Primary Outcome Measures Arms Intervention Arm 1: Secukinumab 2 X 150 mg / 1 mL, subcutaneous (s.c.) injection, randomized in a 1:1 ratio Target Patients Arm 2: Placebo 2X 1 mL, subcutaneous (s.c.) injection, randomized in a 1:1 ratio Patients with moderate-severe Rotator Cuff Tendinopathy Appendix Innovation: Pipeline overview Financial performance Innovation: Clinical trials Cardiovascular, Renal and Metabolic > Immunology Neuroscience Oncology Other Global Health Abbreviations Primary References Readout Milestone(s) 2025 Publication TBD □ NOVARTIS Reimagining Medicine | Arms Intervention Target Patients Readout Milestone(s) Change from BSL in in the Western Ontario Rotator Cuff Index (WORC) Physical Symptom Domain (PSD) score [ Time Frame: At Week 16 ]: - Change in physical shoulder symptoms in participants with moderate to severe RCT at Week 16 Arm 1 experimental: Secukinumab 2 X 150 mg / 1 mL, subcutaneous (s.c.) injection, randomized in a 1:1 ratio Arm 2 placebo: 2 X 1 mL, subcutaneous (s.c.) injection, randomized in a 1:1 ratio Patients with moderate-severe Rotator Cuff Tendinopathy 2025 Publication TBD Novartis Q4 Results | January 31, 2024 58

View entire presentation